Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 10/3099% above fair value
$144.67−3.69 (-2.49%)
Close on Nov 3, 2026Market cap $356.93BP/E 149.1Yield 2.27%
Merck Bravecto — Worldwide reported growth YoY by Year
Bravecto — Worldwide reported growth YoY (%) (%)
Merck Bravecto — Worldwide reported growth YoY: 1.0% in FY2025, down 5.0 pts from a year earlier.
Latest, FY2025
1.0%
Period ended Dec 31, 2025
Change on a year earlier
-5.0 pts
6.0% in FY2024
History
3 years
Since FY2023
Sources
3
Documents cited below
Where the FY2025 figure comes from
“Sales of the Bravecto line of products were $1.1 billion in 2025, an increase of 1% compared with 2024.”
Source: Form 10-K (mrk-20251231.htm, filed 2026-02-24) ↗
Reported in Form 10-Q / 10-K Animal Health MD&A.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Bravecto — Worldwide reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.0% | -5.0 pts | Form 10-K (mrk-20251231.htm, filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 6.0% | +2.0 pts | Form 10-K (mrk-20241231.htm, filed 2025-02-25) ↗ |
| FY2023 | Dec 31, 2023 | 4.0% | – | Form 10-K (mrk-20231231.htm, filed 2024-02-26) ↗ |
Cite this data
StockData. (2026). Merck Bravecto — Worldwide reported growth YoY (%), annual FY2023–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-bravecto-nom-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.
See a number that looks wrong?